Lilly Asia Ventures achieved an exit in a Hong Kong offering in which the oncology therapy developer floated at the top of its range.

Jacobio Pharmaceuticals, a China-based cancer, autoimmune and infectious diseases drug developer backed by pharmaceutical firm Eli Lilly, has floated in a $174m initial public offering, DealStreetAsia has reported. The company issued almost 96.5 million shares on the Hong Kong Stock Exchange priced at HK$14.00 ($1.81) each, at the top of the IPO’s HK$12 to HK$14…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.